Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday, MarketBeat Ratings reports. They presently have a $120.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 42.37% from the stock’s current price.

A number of other analysts have also recently commented on ORKA. Guggenheim reissued a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Piper Sandler reissued an “overweight” rating and set a $180.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $128.91.

Oruka Therapeutics Stock Performance

Shares of ORKA stock traded down $5.64 on Thursday, reaching $84.29. 603,231 shares of the company were exchanged, compared to its average volume of 1,099,712. The company has a market cap of $5.58 billion, a price-to-earnings ratio of -41.26 and a beta of -0.34. The business has a 50-day moving average price of $96.79 and a 200 day moving average price of $75.32. Oruka Therapeutics has a 1 year low of $14.89 and a 1 year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, equities analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Lawrence Klein sold 75,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the transaction, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider owned 31,771 shares in the company, valued at $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 122,950 shares of company stock worth $11,528,806. 23.49% of the stock is owned by insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ORKA. Nykredit A S acquired a new position in Oruka Therapeutics in the 2nd quarter valued at about $29,000. Caitong International Asset Management Co. Ltd acquired a new position in Oruka Therapeutics in the 4th quarter valued at about $67,000. Orion Capital Management LLC acquired a new position in Oruka Therapeutics in the 2nd quarter valued at about $91,000. Royal Bank of Canada boosted its holdings in Oruka Therapeutics by 178.5% in the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after purchasing an additional 2,033 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in Oruka Therapeutics by 119.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock valued at $156,000 after purchasing an additional 1,736 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Strong Week 28 psoriasis results: In the Phase 2a EVERLAST-A trial, ORKA-001 produced deepening responses without additional dosing after Week 4. PASI 100 increased to 71.4% and PASI 90 to 87.3%, while placebo-crossover patients achieved response rates similar to those initially treated with ORKA-001. The drug also maintained a favorable safety and tolerability profile. Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001
• Positive Sentiment: Analysts remain bullish: Wedbush reaffirmed its “outperform” rating and set a $165 price target, while HC Wainwright reiterated “buy” with a $120 target. Both targets imply substantial potential appreciation from recent trading levels and signal confidence in ORKA-001’s development prospects. Wedbush Reaffirms Oruka Rating
• Neutral Sentiment: Additional catalysts are ahead: Oruka expects 16-week EVERLAST-B data in the fourth quarter of 2026 and full 52-week EVERLAST-A data in December 2026. These results should provide further information about durability, efficacy, and safety.
• Negative Sentiment: Positive data did not lift the shares: Despite the stronger Week 28 responses, reports indicated that Oruka’s stock fell, suggesting investors may have been looking for a more immediate or decisive catalyst. The reaction highlights the risks of clinical-stage biotechnology stocks, where valuation depends heavily on future trial outcomes and regulatory progress. Update: Oruka Shares Fall Despite Deepening Week 28 Responses

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.